Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
United States
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland Staten Island University Hospital, Staten Island, New York University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin Austria
Medical University Vienna, Vienna